|
MechanismmAChRs antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date20 Jul 1968 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismComplement system proteins inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
评估低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次给药的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple administrations of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects
主要目的:1)评价低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次滴眼给药的安全性和耐受性。
次要目的:1)评价低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次滴眼给药的血浆药代动力学特征。
[Translation] Primary objective: 1) To evaluate the safety and tolerability of single/multiple eye drops of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects.
Secondary objective: 1) To evaluate the plasma pharmacokinetic characteristics of single/multiple eye drops of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects.
100 Clinical Results associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
0 Patents (Medical) associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
100 Deals associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
100 Translational Medicine associated with Al Health Eye Medicine (Liaoning) Co., Ltd.